Syniad Innovations is Harnessing the Power of Breakthrough Scientific Research to Change the World for the Better

April 8, 2024 | 
Growth Companies

Syniad Innovations is revolutionizing the intersection between University research and real-world applications.

Syniad had a remarkable end to 2023 and a promising first quarter in 2024, demonstrating that hard work in challenging market conditions pays off. Specializing in chemistry and computational science, Syniad has developed a unique approach to identifying and nurturing high-potential ventures with the aim of driving global impact. By carefully selecting ventures aligned with their investment thesis, which prioritizes sustainability and innovation, Syniad demonstrates a commitment to not only generating financial returns but also contributing to positive societal change. This dedication to both financial success and societal impact sets Syniad apart as a leader in the field of venture creation.



One of Syniad’s notable strategies is its adept use of non-dilutive funding sources to mitigate early-stage venture risks effectively. Leveraging programs such as Canada’s Industrial and Technological Benefits Policy, Syniad secures contributions from defense procurement obligations, providing a strong financial foundation for its ventures. This strategic financing approach enables Syniad to deploy capital efficiently, maximizing the potential for generating significant returns on investment.


A Deep Dive into Syniad’s Portfolio of Ventures


Anodyne Chemistries recently closed its seed capital round, fully subscribed, marking a testament to outstanding technical progress. This milestone validates Anodyne’s enzymatic chemistry platform’s ability to convert CO2 into valuable chemicals, attracting early industry attention and paving the way for pilot scale production. Through innovative catalysis technology, Anodyne has pioneered the design of de novo enzymes, accelerating biochemical reactions through AI-powered simulations—a breakthrough with far-reaching implications for sustainable chemical manufacturing.


Gemina Labs’ groundbreaking chemistry platform for point-of-care diagnostics holds promise for revolutionizing healthcare accessibility worldwide. Gemina recently closed a bridge round, provided a strategic market update, and secured its first major partnership agreement. This culmination of three years of dedicated effort demonstrates Gemina’s growth trajectory, with plans to expand its technology platform into molecular diagnostics.


Patronus Technologies has bolstered its AI team, enhancing its capabilities in advanced materials development. Leveraging probabilistic AI models, Patronus is revolutionizing materials R&D, attracting top talent with expertise in AI and heterogeneous materials modeling. These developments signal a new era in materials science, positioning Patronus as a key player in developing next-generation protective materials for defense and conventional markets.


Syniad’s success is further bolstered by its experienced leadership team, including individuals with a proven track record of building successful ventures and securing strategic partnerships. From John Davies’ extensive experience in creating science-intensive companies to Martin Cronin’s proficiency in navigating complex funding landscapes, Syniad benefits from a wealth of expertise that positions it for continued growth and impact in the ever-evolving landscape of scientific innovation.


Syniad Innovations stands at the forefront of translating cutting-edge research into practical solutions that address global challenges while driving economic growth. Looking ahead, Syniad is set on expanding beyond Canada, as well as seeking collaborations with leading Universities and research laboratories globally while forging connections between their ventures and industrial receptors worldwide. Thank you John Davies for sharing Syniad’s story of innovation, sustainability, and global impact, cementing Syniad’s reputation as a leader in the field of scientific venture creation.


Learn more about Syniad’s Ventures


Anodyne Chemistries leads sustainable innovation by converting CO2 waste into valuable chemicals through enzymatic chemistry and catalysis technology. Their focus on eco-friendly solutions and efficient production methods drives a transition toward a more sustainable future.
Learn more.




Gemina Labs specializes in point-of-care diagnostics, expanding into molecular diagnostics for broader medical applications. Their advanced technologies aim to provide rapid and accurate diagnostic solutions, revolutionizing healthcare accessibility. Learn more.



Patronus Technologies  excels in developing next-generation protective materials, utilizing advanced computational modeling to innovate solutions for defense and conventional markets. Their multidisciplinary team ensures cutting-edge advancements in materials science. Learn more.




To continue to follow Syniad’s groundbreaking innovations, please submit your name and email below.

Get in touch with John Davies:


Disclosure & Disclaimer
International Deal Gateway (“IDG”) has been paid by Syniad Innovations Inc. (“Syniad”) to provide various marketing and awareness services including posting content and conducting interviews on or through our platform and e-mail subscriber list. We do not own any securities of Syniad. You should not make any investment decisions based on our communications. 
The information contained herein relating to Syniad has been prepared by or on behalf of Syniad and the information regarding Syniad is being provided to you by IDG at the direction of, and on behalf of Syniad.
We are NOT securities dealers or brokers, investment advisors or financial advisors, and you should not rely on the information herein as investment advice. If you are seeking personal investment advice, please contact a qualified and registered broker, investment advisor or financial advisor.
At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. By using our website or platform you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.
We do not provide personalized or individualized investment advice or advice that is tailored to the needs of any particular recipient. Any information provided as part of the services is impersonal and not specific to any person’s investment needs. You acknowledge and agree that no content published or otherwise provided as part of any service constitutes a personalized recommendation or advice regarding the suitability of, or advisability of investing in, purchasing or selling any particular investment, security, portfolio, commodity, transaction or investment strategy. To the extent that any of the content may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person.
This content (including interviews) may include certain statements that constitute “forward-looking information or statements” and readers and viewers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. There are risks and other factors that could cause actual results and events to vary significantly.
The content disclosed herein is intended to highlight Syniad for your further investigation; this is not a stock recommendation or constitute an offer or sale of the referenced securities. The securities of Syniad may be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the company’s SEDAR and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR and SEC filings, company websites, and other publicly available sources. The information in our website / media webpage is believed to be accurate and correct and we have asked Syniad to review the contents as it relates to them, but has not been independently verified and is not guaranteed to be correct.
This email does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America.
Forward-looking statements
Certain statements in this press release constitute “forward looking” statements that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, objectives or achievements of Syniad, or industry results, to be materially different from any future results, performance, objectives, or achievements expressed or implied by such forward looking statements. When used in this press release, words such as “may”, “would”, “could”, “will”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan”, and other similar expressions are intended to identify forward-looking statements. These statements reflect Syniad’s current views regarding future events and operating performance, are based on information currently available to Syniad, and speak only as of the date of this press release.
These forward-looking statements involve a number of risks, uncertainties and assumptions and should not be read as guarantees that future performance or results will be achieved. Many factors could cause the actual results, performance, objectives, or achievements of Syniad to be materially different from any future results, performance, objectives, or achievements that may be expressed or implied by such forward looking statements.  Additional factors are discussed under the headings “Liquidity and capital resources” and “Risks and Uncertainties” in Syniad management’s discussion and analysis, annual information form, and other publicly available disclosure documents, as filed by Syniad on SEDAR (
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described in this presentation as intended, planned, anticipated, believed, estimated, or expected. Unless required by applicable securities law, Syniad does not intend and does not assume any obligation to update these forward-looking statements.